AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36941621 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet (ICKD) for 4 weeks
Number of subjects: 6
Study 36941621 — intervention group
Group type: COMPARATOR
Intervention: Usual mixed Western-style diet (UD) for 4 weeks
Number of subjects: 6
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT Sero-K-Set
Number of subjects: 2345
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: rHAT Sero-Strip
Number of subjects: 2345
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: SD Bioline HAT
Number of subjects: 2345
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one clinical presentation (swollen lymph nodes, important weight loss, severe itching, motor disorders)
Number of subjects: 2345
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypanolysis on DBS
Number of subjects: 2345
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA/T.b. gambiense on DBS
Number of subjects: 2345
Study 36941656 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP and m18S qPCR
Number of subjects: 2345
Study 36941683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) ventilation at low PEEP (5 cmH2O)
Number of subjects: 30
Study 36941683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) ventilation at high PEEP
Number of subjects: 30
Study 36941683 — intervention group
Group type: COMPARATOR
Intervention: Interrupted events due to high baseline ICP
Number of subjects: 30
Study 36941683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 30
Study 36941714 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive drainage
Number of subjects: 304
Study 36941714 — intervention group
Group type: COMPARATOR
Intervention: Fixed-time drainage
Number of subjects: 304
Study 36942507 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP1128 single dose (0.3-10 mg)
Number of subjects: 49
Study 36942507 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP1128 multiple dose (3-100 mg)
Number of subjects: 49
Study 36942507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 49
Study 36942507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple dose)
Number of subjects: 49
Study 36942533 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC (1 mL/kg, 25 IU of factor IX/kg)
Number of subjects: 324
Study 36942533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL/kg saline solution)
Number of subjects: 324
Study 36942533 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC
Number of subjects: 324
Study 36942533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 36942550 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 3320
Study 36942550 — intervention group
Group type: COMPARATOR
Intervention: Usual care pharmacologic thromboprophylaxis
Number of subjects: 3320
Study 36942628 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolution Neural Network (CNN) algorithm for diagnosing shockable rhythms
Number of subjects: 1005
Study 36942628 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolution Neural Network (CNN) algorithm for diagnosing nonshockable rhythms
Number of subjects: 1005
Study 36942628 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolution Neural Network (CNN) algorithm performance against noise artifacts
Number of subjects: 1005
Study 36942628 — intervention group
Group type: COMPARATOR
Intervention: CNN algorithm compared to adjudicators for classifying atrial arrhythmias as nonshockable
Number of subjects: 1005
Study 36942651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizanani trial participants
Number of subjects: 1143
Study 36942721 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital approach using intraoral scanner (IOS)
Number of subjects: 31
Study 36942721 — intervention group
Group type: COMPARATOR
Intervention: Analog approach using polyvinyl siloxane impression material
Number of subjects: 31
Study 36942757 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaterals originating from NIRA
Number of subjects: 93
Study 36942757 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaterals originating from IRA proximal to the acute STEMI occlusion
Number of subjects: 93
Study 36942757 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaterals originating from IRA distal to the acute occlusion
Number of subjects: 93
Study 36942789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (200 mg daily for either 4 or 7 days, followed by tapering for a total of 8 or 14 days)
Number of subjects: 795
Study 36942789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795
Study 36942789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone
Number of subjects: 795
Study 36942937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib, oral metronomic cyclophosphamide, and dexamethasone
Number of subjects: 12
Study 36943075 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE CMR analyzed by machine-learning algorithm
Number of subjects: 761
Study 36943075 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE CMR analyzed by humans
Number of subjects: 761
Study 36943075 — intervention group
Group type: COMPARATOR
Intervention: Guideline criterion (LVEF of ≤35% and New York Heart Association class II or III)
Number of subjects: 761
Study 36943168 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-based phosphene mapping
Number of subjects: 3
Study 36943168 — intervention group
Group type: COMPARATOR
Intervention: Finger-based phosphene mapping
Number of subjects: 3
Study 36943214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postpartum IUD placement (2 to 4 weeks postpartum)
Number of subjects: 404
Study 36943214 — intervention group
Group type: COMPARATOR
Intervention: Interval IUD placement (6 to 8 weeks postpartum)
Number of subjects: 404
Study 36943254 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 156
Study 36943254 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 156
Study 36943309 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal Tissue Addition Keratoplasty (CTAK)
Number of subjects: 18
Study 36943345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise training intervention
Number of subjects: 150
Study 36943345 — intervention group
Group type: COMPARATOR
Intervention: 6-month stretching intervention (control)
Number of subjects: 150
Study 36943360 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital whiteboard (E-paper)
Number of subjects: 110
Study 36943374 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning group
Number of subjects: 28
Study 36943374 — intervention group
Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 28
Study 36943374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 36943405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 0
Study 36943437 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor evoked potentials (MEPs) measured twice, 2 weeks apart, every 6 months.
Number of subjects: 10
Study 36943437 — intervention group
Group type: EXPERIMENTAL
Intervention: TA latency and amplitude with facilitation
Number of subjects: 10
Study 36943437 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps latency with facilitation
Number of subjects: 10
Study 36943437 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal correlations of MEPs
Number of subjects: 10
Study 36943669 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of monocyte/macrophage and endothelial activation markers, chemotaxis, and hematopoietic cytokines
Number of subjects: 0
Study 36943669 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency of central memory CD4 T cells
Number of subjects: 0
Study 36943669 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiles
Number of subjects: 0
Study 36943907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 2031
Study 36943907 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 2031
Study 36944059 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin Fc (BIF) once weekly
Number of subjects: 278
Study 36944059 — intervention group
Group type: COMPARATOR
Intervention: Insulin Degludec once daily
Number of subjects: 278
Study 36944116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (Peg-IFN)
Number of subjects: 0
Study 36944116 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36944128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transcutaneous Injection in the Lacrimal Gland
Number of subjects: 0
Study 36944142 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug/LA group (laser acupuncture therapy for 20 minutes per session, three sessions weekly, plus calcium and vitamin D 3 supplement containing fluoride)
Number of subjects: 68
Study 36944142 — intervention group
Group type: COMPARATOR
Intervention: Drug-only group (calcium and vitamin D 3 supplement containing fluoride)
Number of subjects: 68
Study 36944357 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 587
Study 36944357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study 36944461 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate-heparin lock solution
Number of subjects: 462
Study 36944461 — intervention group
Group type: COMPARATOR
Intervention: Heparin-only lock solution
Number of subjects: 462
Study 36944463 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose infusion of low-molecular weight iron dextran (1000 mg)
Number of subjects: 0
Study 36944463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study 36944485 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention arm of the RCT (BabySMART)
Number of subjects: 106
Study 36944559 — intervention group
Group type: EXPERIMENTAL
Intervention: bCTC count ≥3
Number of subjects: 589
Study 36944559 — intervention group
Group type: EXPERIMENTAL
Intervention: bCTC count <3
Number of subjects: 589
Study 36944559 — intervention group
Group type: COMPARATOR
Intervention: anti-VEGF treatment
Number of subjects: 589
Study 36944559 — intervention group
Group type: COMPARATOR
Intervention: anti-EGFR treatment
Number of subjects: 589
Study 36944583 — intervention group
Group type: EXPERIMENTAL
Intervention: NIFECG
Number of subjects: 285
Study 36944583 — intervention group
Group type: COMPARATOR
Intervention: cCTG
Number of subjects: 285
Study 36944694 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with serratus anterior plane block (SAM) and pectoral nerve block type I (PECS I)
Number of subjects: 0
Study 36944694 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 0
Study 36944694 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with SAM + PECS I
Number of subjects: 0
Study 36944848 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (T)
Number of subjects: 0
Study 36944848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (L)
Number of subjects: 0
Study 36944848 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Lapatinib (TL)
Number of subjects: 0
Study 36944851 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually augmented self-hypnosis using virtual reality (VR) with the 'Aqua' module (Oncomfort™)
Number of subjects: 100
Study 36944851 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study 36944851 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually augmented self-hypnosis using virtual reality (VR)
Number of subjects: 100
Study 36944930 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) intervention, 5-min duration via telehealth using a head-mounted immersive device.
Number of subjects: 120
Study 36944929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac rhythm monitoring with insertable cardiac monitor (Reveal LINQ, Medtronic) for atrial fibrillation (AF) detection
Number of subjects: 250
Study 36944956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei K56
Number of subjects: 74
Study 36944956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 36944986 — intervention group
Group type: COMPARATOR
Intervention: Center-based intervention group (CBI)
Number of subjects: 325
Study 36944986 — intervention group
Group type: COMPARATOR
Intervention: Center-based plus home-based intervention group (CBI+HBI)
Number of subjects: 325
Study 36944986 — intervention group
Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 325
Study 36945034 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion
Number of subjects: 24
Study 36945034 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 24
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of IL-8
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of IL-10
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of CAIX
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of ADA
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of CASP8
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of FasL
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-1
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC16
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: TFNSFR4
Number of subjects: 136
Study 36945037 — intervention group
Group type: EXPERIMENTAL
Intervention: CD244
Number of subjects: 136
Study 36945146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully digital continuous self-screening for AF using a patch ECG device (ECG247 Smart Heart Sensor)
Number of subjects: 2118
Study 36945200 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM platelet aggregation using ARATEM
Number of subjects: 40
Study 36945200 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM platelet aggregation using ADPTEM
Number of subjects: 40
Study 36945200 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM platelet aggregation using TRAPTEM
Number of subjects: 40
Study 36945200 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Danish population
Number of subjects: 40
Study 36945217 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-responsive phenomic alteration-related driver genes (PARGs) identified in the XYZ phenome
Number of subjects: 0
Study 36945217 — intervention group
Group type: EXPERIMENTAL
Intervention: Driver genes detected
Number of subjects: 0
Study 36945475 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced lipid emulsion dosing
Number of subjects: 0
Study 36945475 — intervention group
Group type: COMPARATOR
Intervention: Usual lipid emulsion dosing
Number of subjects: 0
Study 36945495 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care intravenous cytotoxic chemotherapy
Number of subjects: 200
Study 36945495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered health data aggregating platform
Number of subjects: 200
Study 36945579 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg)
Number of subjects: 30
Study 36945773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual CAR T cells targeting CD19 and CD22 (obe-cel)
Number of subjects: 0
Study 36945773 — intervention group
Group type: COMPARATOR
Intervention: Single CAR targeting CD19
Number of subjects: 0
Study 36945773 — intervention group
Group type: COMPARATOR
Intervention: Single CAR targeting CD22
Number of subjects: 0
Study 36945823 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent music reward therapy (GC-MRT)
Number of subjects: 105
Study 36945823 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 105
Study 36945823 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 105
Study 36945997 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lavender oil
Number of subjects: 180
Study 36945997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 36945997 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 36946138 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study 36946232 — intervention group
Group type: COMPARATOR
Intervention: High-Dose Prophylactic Anticoagulation (HD-PA)
Number of subjects: 334
Study 36946232 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Anticoagulation (TA)
Number of subjects: 334
Study 36946232 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Prophylactic Anticoagulation (SD-PA)
Number of subjects: 334
Study 36946237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedopi
Number of subjects: 0
Study 36946293 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 1684
Study 36946293 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D index scores 0.800 or more
Number of subjects: 1684
Study 36946293 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher EQ-5D index scores
Number of subjects: 1684
Study 36946298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone treatment, dosage and duration not available
Number of subjects: 0
Study 36946298 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36946321 — intervention group
Group type: EXPERIMENTAL
Intervention: Local flaps
Number of subjects: 30
Study 36946321 — intervention group
Group type: COMPARATOR
Intervention: Skin grafts
Number of subjects: 30
Study 36946321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study 36946359 — intervention group
Group type: EXPERIMENTAL
Intervention: dPTFE (partially exposed non-absorbable membrane)
Number of subjects: 44
Study 36946359 — intervention group
Group type: COMPARATOR
Intervention: USH (unassisted socket healing)
Number of subjects: 44
Study 36946420 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention focused on caloric restriction, increased physical activity, and diet
Number of subjects: 5145
Study 36946420 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5145
Study 36946440 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home aerobic and/or resistance exercise intervention for 16 weeks
Number of subjects: 24
Study 36946443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aducanumab (10 mg/kg) in EMERGE
Number of subjects: 3285
Study 36946443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aducanumab
Number of subjects: 3285
Study 36946443 — intervention group
Group type: COMPARATOR
Intervention: High-dose aducanumab in ENGAGE
Number of subjects: 3285
Study 36946443 — intervention group
Group type: EXPERIMENTAL
Intervention: Later enrolled patients randomized to target dosing regimen of 10 mg/kg
Number of subjects: 3285
Study 36946448 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenezumab (Phase 2 studies ABBY and BLAZE)
Number of subjects: 463
Study 36946448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Phase 2 studies ABBY and BLAZE)
Number of subjects: 463
Study 36946505 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination (BV) using inactivated virus vaccines (the third dose)
Number of subjects: 114
Study 36946505 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 114
Study 36946603 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg solanezumab every 4 weeks for 80 weeks
Number of subjects: 3
Study 36946603 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 80 weeks
Number of subjects: 3
Study 36946605 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/Samidorphan
Number of subjects: 0
Study 36946605 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36946749 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW-PDT
Number of subjects: 31
Study 36946749 — intervention group
Group type: COMPARATOR
Intervention: IAA-PDT
Number of subjects: 31
Study 36947030 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented double wide-area circumferential ablation (WACA)
Number of subjects: 398
Study 36947030 — intervention group
Group type: COMPARATOR
Intervention: Standard single wide-area circumferential ablation (WACA)
Number of subjects: 398
Study 36947036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severity cluster
Number of subjects: 706
Study 36947036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-severity cluster
Number of subjects: 706
Study 36947036 — intervention group
Group type: COMPARATOR
Intervention: Low-severity cluster
Number of subjects: 706
Study 36947036 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic effects
Number of subjects: 706
Study 36947042 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lovastatin 2% plus cholesterol 2% cream (lovastatin-cholesterol); applied once or twice daily for 12 weeks
Number of subjects: 32
Study 36947042 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lovastatin 2% cream (lovastatin); applied once or twice daily for 12 weeks
Number of subjects: 32
Study 36947042 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 32
Study 36947042 — intervention group
Group type: COMPARATOR
Intervention: Adverse events reported in both groups
Number of subjects: 32
Study 36947125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving trained community health workers conducting home visits and providing support for PWUD and their families.
Number of subjects: 60